Ares Financial Consulting
SYRE icon

Ares Financial Consulting’s Spyre Therapeutics SYRE Stock Holding History

Ares Financial Consulting’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-11
Closed -$977 – 1133
2026
Q2 		$977 Buy
+11
New +$803 ﹤0.01% 1012

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Ares Financial Consulting's SYRE Position: Q3 2026 in Review

Ares Financial Consulting sold out of Spyre Therapeutics (SYRE) in Q3 2026, closing a stake of 11 shares — an estimated $977 sold.

Ares Financial Consulting first reported a position in SYRE in Q2 2026 and held it in 1 quarter. The position peaked at $977 in Q2 2026. 114 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Ares Financial Consulting reported no remaining Spyre Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 11 Spyre Therapeutics shares in Q3 2026, an estimated $977.
  • Ares Financial Consulting first reported a position in Spyre Therapeutics in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Spyre Therapeutics position peaked at $977 in Q2 2026.
  • 114 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.